November 24, 2016 - By Marie Mckinney · 0 Comments
The stock of Anika Therapeutics Incorporated (NASDAQ:ANIK) registered an increase of 0.48% in short interest. ANIK’s total short interest was 899,900 shares in November as published by FINRA. Its up 0.48% from 895,600 shares, reported previously. With 102,900 shares average volume, it will take short sellers 9 days to cover their ANIK’s short positions. The short interest to Anika Therapeutics Incorporated’s float is 6.8%. The stock increased 1.30% or $0.6 on November 23, hitting $46.73. About 77,125 shares traded hands. Anika Therapeutics Inc (NASDAQ:ANIK) has declined 2.40% since April 22, 2016 and is downtrending. It has underperformed by 7.81% the S&P500.
Anika Therapeutics, Inc. is an orthopedic medicines company. The company has a market cap of $685.13 million. The Firm offers therapeutic pain management solutions. It has a 20.03 P/E ratio. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid technology.
Insitutional Activity: The institutional sentiment increased to 1.26 in Q2 2016. Its up 0.45, from 0.81 in 2016Q1. The ratio improved, as 16 funds sold all Anika Therapeutics Inc shares owned while 57 reduced positions. 11 funds bought stakes while 48 increased positions. They now own 11.10 million shares or 8.05% less from 12.07 million shares in 2016Q1.
The Massachusetts-based Numeric Limited Liability Corp has invested 0.13% in Anika Therapeutics Inc (NASDAQ:ANIK). Geode Mgmt Ltd Co holds 111,844 shares or 0% of its portfolio. Renaissance Group Inc Ltd Com holds 0.02% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK) for 6,558 shares. First Quadrant Lp Ca owns 13,400 shares or 0.02% of their US portfolio. Royal National Bank & Trust Of Canada reported 38,330 shares or 0% of all its holdings. Gabelli Funds Limited owns 7,000 shares or 0% of their US portfolio. California Pub Employees Retirement Sys last reported 0.01% of its portfolio in the stock. Seaward Mngmt L P last reported 0.09% of its portfolio in the stock. Stifel, a Missouri-based fund reported 10,812 shares. Turner Invs Limited Partnership, a Pennsylvania-based fund reported 45,000 shares. Eaton Vance accumulated 6,013 shares or 0% of the stock. Credit Suisse Ag has invested 0% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK). The New Jersey-based Oaktop Cap Mgmt Ii L P has invested 0.16% in Anika Therapeutics Inc (NASDAQ:ANIK). Cornerstone Mgmt Ltd Liability Company accumulated 0.01% or 12,600 shares. The Minnesota-based Ameriprise Financial has invested 0% in Anika Therapeutics Inc (NASDAQ:ANIK).
Insider Transactions: Since November 7, 2016, the stock had 0 insider purchases, and 1 insider sale for $23,432 net activity. 540 Anika Therapeutics Inc (NASDAQ:ANIK) shares with value of $23,432 were sold by BOWER JOSEPH I.
Out of 3 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Anika Therapeutics has been the topic of 6 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Northland Capital maintained the stock with “Outperform” rating in Friday, February 26 report. Barrington Research initiated Anika Therapeutics Inc (NASDAQ:ANIK) on Monday, October 12 with “Outperform” rating. The stock of Anika Therapeutics Inc (NASDAQ:ANIK) has “Equal Weight” rating given on Friday, August 28 by First Analysis. The firm has “Hold” rating by Zacks given on Wednesday, August 26. The stock of Anika Therapeutics Inc (NASDAQ:ANIK) has “Market Perform” rating given on Wednesday, April 27 by Northland Capital. The stock has “Outperform” rating given by Northland Capital on Thursday, July 30.
Anika Therapeutics, Inc., incorporated on February 28, 1992, is an orthopedic medicines company. The Firm offers therapeutic pain management solutions. The Firm is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. The Firm offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
More recent Anika Therapeutics Inc (NASDAQ:ANIK) news were published by: Businesswire.com which released: “Anika Therapeutics, Inc. Announces First Patient Enrolled in FastTRACK Phase …” on December 29, 2015. Also Businesswire.com published the news titled: “Anika Therapeutics Delivers Strong Performance with Record Product Revenue for …” on February 24, 2016. Businesswire.com‘s news article titled: “Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain …” with publication date: June 01, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney